The group's principal activity is to provide commercialize effective gene therapies for the treatment of serious and chronic human diseases. The group's products include lentiviral gene deliver, lentiglobin (tm) for thalassemia, lentiglobin (tm) for sickle cell disease and pipeline. The group operates from the United States.
